http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
New Data Show Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice
-
Veracyte (VCYT) Reports Publication Reinforcing Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
-
Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier for Informing Treatment of Men Experiencing Prostate Cancer Progression
-
Veracyte (VCYT) Announces New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal Cancer
-
Veracyte Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal Cancer
-
New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier
-
Veracyte (VCYT) Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay’s Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors
-
Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay’s Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors
-
Veracyte to Present at Upcoming Investor Conferences
-
Veracyte (VCYT) Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment
-
Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment
-
Updated AUA/ASTRO Guideline Includes Supportive Statement for Use of Genomic Tests, Including Decipher Prostate, for Men With Localized Prostate Cancer
-
Veracyte Announces that Data for Its Genomic and Immuno-Oncology Offerings Will Be Highlighted at the 2022 ASCO Annual Meeting
-
Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022
-
Veracyte Announces First Quarter 2022 Financial Results
-
Envisia Genomic Classifier Highlighted in Updated Clinical Practice Guideline Regarding Idiopathic Pulmonary Fibrosis Diagnosis
-
Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors
-
Veracyte Announces New Urologic Cancer Data To Be Presented at AUA 2022 International Conference
-
Veracyte Announces New Performance Data for the Percepta Nasal Swab Test To Be Presented at ATS 2022 International Conference
-
Veracyte to Release First Quarter 2022 Financial Results on May 3, 2022
-
Veracyte to Participate in the Cowen 42nd Annual Health Care Conference
-
Veracyte Announces Fourth Quarter and Full-Year 2021 Financial Results
-
Veracyte Appoints Annie McGuire as General Counsel
-
Veracyte Appoints Jonathan Wygant as Chief Accounting Officer
-
Veracyte to Release Fourth Quarter and Full-Year 2021 Financial Results on February 28, 2022
-
New Data Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy In Men with Intermediate-Risk Prostate Cancer
-
Veracyte to Participate in 11th Annual SVB Leerink Global Healthcare Conference
-
Veracyte Announces New Data to be Presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium
-
Veracyte (VCYT) Announces New Data Suggest Percepta Genomic Sequencing Classifier Can Help Accelerate Timely Treatment for Patients with Early-Stage Lung Cancer
-
New Data Suggest Veracyte’s Percepta Genomic Sequencing Classifier Can Help Accelerate Timely Treatment for Patients with Early-Stage Lung Cancer
-
Veracyte (VCYT) Announces Key Leadership Promotions to Advance Its Strategic Global Vision
-
Veracyte Announces Key Leadership Promotions to Advance Its Strategic Global Vision
-
Veracyte Announces Publication of Data Demonstrating Clinical Utility of Its Envisia Genomic Classifier to Improve IPF Diagnosis
-
Veracyte (VCYT) Announces Further Reimbursement Expansion for Prosigna Breast Cancer Test in Europe
-
Veracyte Announces Further European Reimbursement Expansion for Prosigna Breast Cancer Test
-
Veracyte Announces New Data on Immuno-Oncology Offerings Presented at SITC 2021
-
Veracyte Announces Third Quarter 2021 Financial Results
-
Veracyte (VCYT) Announces Immunoscore Colon Cancer Test Included in ESMO Clinical Practice Guidelines Adapted for Pan-Asia
-
Veracyte Announces Immunoscore Colon Cancer Test Included in ESMO Clinical Practice Guidelines Adapted for Pan-Asia
-
Veracyte (VCYT) Announces New Publication Reinforcing Clinical Utility of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis
-
New Publication Reinforces Clinical Utility of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis
-
Veracyte Announces New Data To Be Presented at SITC 2021 Will Highlight Company’s Immuno-Oncology Capabilities
-
New Data Demonstrate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier in Tailoring Treatment for Prostate Cancer Patients Experiencing Progression After Surgery
-
Data Presented at ASTRO 2021 Validate Prognostic Value of Decipher Prostate Genomic Test in Newly Diagnosed, Clinically High-Risk Prostate Cancer
-
Veracyte (VCYT) Announces New Data Validating Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
-
New Data to be Presented at ASTRO 2021 Further Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
-
New Publication Demonstrates Ability of Veracyte’s Decipher Bladder Test to Identify Tumors Most Likely to Respond to Chemotherapy
-
Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021
-
Veracyte (VCYT) Announces New Clinical Utility Data Confirm its Envisia Genomic Classifier Increases Accuracy and Confidence in IPF Diagnosis
-
New Clinical Utility Data Confirm Veracyte’s Envisia Genomic Classifier Increases Accuracy and Confidence in IPF Diagnosis
